Health
CureVac’s Covid-19 vaccine induces immune response in study – Clinical Trials Arena
CureVac has reported that the ongoing Phase I study of its Covid-19 vaccine candidate CVnCoV showed that it was well-tolerated across all tested doses ranging from…
CureVac has reported that the ongoing Phase I study of its Covid-19 vaccine candidate CVnCoV showed that it was well-tolerated across all tested doses ranging from 2 to 12µg and induced strong binding and neutralising antibody responses.
The Phase I study is evaluating the safety, reactogenicity and immunogenicity of the investigational vaccine CVnCoV, an optimised, non-chemically modified mRNA that encodes the prefusion stabilised full-length spike protein of the SARS-CoV-2 virus.
Its mode of action…
-
Noosa News23 hours agoAustralia’s newest rice mill funded largely by farmers
-
Noosa News16 hours agoDaly Cherry-Evans set to be dropped as Maroons captain
-
General22 hours agoBusinesses and consumers caught between opposing forces
-
Noosa News15 hours agoThe Story Bridge should serve as a warning – and an opportunity